Stergios J. Moschos

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis

  Journal of Neuro-Oncology · 2026-02-01

• Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

  2025-12-11

• Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

  2025-12-11

• Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma

  The American Journal of Surgical Pathology · 2025-11-19

• 799 Dissecting the role of folate receptor beta-mediated one-carbon metabolism in tumor-associated macrophages

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4

  Immunity · 2025-09-25 · 29 citations

• Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types

  Diagnostic and Interventional Imaging · 2025-08-05

• SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Abstract 2051: Baseline and adaptive activated kinome profiling identifies PTK6 as a mediator of resistance to vemurafenib and dabrafenib but not encorafenib in <i>BRAFV600</i>-mutant metastatic melanoma

  Cancer Research · 2025-04-21

• Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204

  Journal of Clinical Oncology · 2025-01-03 · 5 citations

• Interferon Therapy For Melanoma

  2024-12-15

• 1465 Denosumab improves clinical benefit of PD1 inhibitors in metastatic melanoma (MM) presumably via a suppressive effect on immunoregulatory myeloid cell populations

  2024-11-01 · 1 citations

• TMIC-81. AN IMMUNOSUPPRESSIVE MACROPHAGE NICHE MAY DRIVE T CELL DYSFUNCTION AND IMMUNOTHERAPY RESISTANCE IN MELANOMA BRAIN METASTASES

  Neuro-Oncology · 2024-11-01

• DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance

  JCO Precision Oncology · 2024-11-01 · 6 citations